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1. Introduction 
Carbonic anhydrases (CAs; EC 4.2.1.1) are ubiquitous metalloenzymes known for decades to be 
involved in the reversible hydration of CO2 to bicarbonate and H+ ions.1,2 This simple reaction plays a 
key role in many crucial physiologic functions connected to metabolic pathways in which CO2 is 
involved.3-6 For this reason, their modulation is used for a long time in the treatment of different diseases 
such as glaucoma,7 edema,8 epilepsy9 and, more recently, inhibitors of CAs are used as a new approach 
for treatment of neuropathic pain,10,11 cerebral ischemia12 and different forms of tumor.13 Conversely, the 
activation of CAs was been for a long time a debated issue and only in recent years it has been started an 
exploration of their possible pharmacological applications.2,14 Histamine (Figure 1) was one of the first 
CA activator (CAA) discovered15 and also one of the most investigated scaffold for designing novel 
ones.16,17 X-ray crystal structure of CA-Histamine has been reported in the 90’s showing the mechanism 
of activation, where the molecule participates to the rate-determining step of the catalytic cycle, 
facilitating the formation of the nucleophilic species of the enzyme.15 In the last years, our group 
focused on new molecules with activating propriety against CAs, most of which amines of the general 
formula Ar–CH2CH(R)NHR’.18-20 In a recent study from our group,21 psychoactive drugs such as 
amphetamine and related compounds (Figure 1) showed strong activating proprieties against different 
CA isoforms. 
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Figure 1. Examples of CAAs: Histamine, Histidine, Amphetamine and Methamphetamine. 
In order to continue our studies in this less investigated field, we synthetized, for the first time, organic 
chalcogenides structurally related to the psychoactive drug Amphetamine. We sought to use N-H 
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unactivated aziridines in reactions with suitable nucleophiles for preparing these derivatives. Indeed, 
ring opening reactions of strained heterocycles with chalcogen nucleophiles, including silyl 
chalcogenides22-27 represents a versatile way to obtain a large variety of biologically and synthetically 
valuable organosulfur,28 organoselenium,29 and organotellurium30 compounds. 
2. Results and discussion 
2.1 Compounds Design and Synthesis. 
We began our investigations by establishing the conditions required to obtain aminosulfide 2a through 
the ring opening reaction of 2-methylaziridine 2a with thiophenol 1a. Among several organic or 
inorganic bases (Et3N, DMAP, Cs2CO3/TBAI) and solvents (THF, CH2Cl2) evaluated, the use of KOH 
in DMF proved to be the most effective conditions in promoting the desired transformation, allowing to 
access 3a in acceptable yield. Evaluation of different temperatures (-15°C, r.t.) gave no yield 
improvement. Having found suitable conditions for the synthesis of β-aminosulfides bearing a free 
amino function, we next explored the scope of this procedure. Thus, o-, m-, and p-bromothiophenol (1b-
d) were smoothly converted into the corresponding β-aminosulfides 3b-d upon reaction with 2a under 
the same conditions. Interestingly, the yield proved to be strongly influenced by the position of the 
bromine on the aromatic ring, increasing from 44% (for the more hindered o-Br-C6H4 substituent) to 
63% (for the less hindered p-Br-C6H4). Furthermore, the reaction of 2-mercaptopyrimidine 1e with 2-
methylaziridine resulted in the formation of the heteroaromatic aminosulfide 3e. In order to evaluate the 
effect of the substituent on the stereogenic centre and to further enlarge the scope of the reaction, we 
also synthesized enantioenriched aminosulfides 3f,g from thiophenol and (S)-N-H aziridines 2b,c. 
Having obtained different novel sulfur-containing hCA activator candidates, we next evaluated the 
reactivity of selenols31,32 with 2-methylaziridine, in order to access new β-aminoselenides with potential 
activity as hCA activators. Therefore, a series of differently substituted aryl selenols (4a-g) were treated 
with aziridines 2a in the presence of KOH to afford the corresponding β-aminoselenides 5a-g. 
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Furthermore, chiral enantioenriched β-phenylseleno amines 5h,i were successfully achieved from the 
corresponding (S)-aziridines 2b,c and benzeneselenol 4a. These findings describe the first example of 
ring opening reaction of N-unactivated aziridines with stable aryl selenols. 
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Scheme 1: Synthesis of β-amino sulfides 3a-g and β-amino selenides 5a-i from N-H aziridines, Yields 
refer to isolated products 
Having synthesised a wide variety of arylthio- and arylseleno-amines, we also investigated the reactivity 
of unprotected aziridines with tellurium-containing nucleophiles. Owing to the instability of tellurols, we 
sought to exploit the reactivity of in situ generated aryltellurolate anions. Thus, differently substituted 
diaryl ditellurides 6a-e were treated with NaBH4 and, then, reacted with N-H aziridine 2a, affording the 
corresponding β-amino aryltellurides 7a-e, bearing different substituted phenyl rings (7a-d) or the 
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naphthyl group (7e). Furthermore, enantioenriched β-phenyltelluro amines 7e,f were achieved from 
ditelluride 6a and (S)-2-benzyl- or (S)-2-isopropyl-aziridine, respectively. 
Te
NH2
Te
NH2
Te
NH2 Te
NH2
H3CO
H3CO
OCH3
H3CO
Te
NH2
Ph Te
NH2
7a, 53% 7b, 65% 7c, 70% 7d, 61%
R
NH2
ArTe
NaBH4
 
(3.0 eq.)
EtOH
0°C, 10 min
ArTe
7f, 57% 7g, 60%
6a-e
Ar Te Te
Ar
0°C to r.t., 2 h
7a-g
H
N
R
2a-c
2a: R = Me
2b: R = (S)-Bn
2c: R = (S)-iPr
Te
NH2
7e, 55%
 
Scheme 2. Synthesis of β-amino tellurides 7a-g from N-H aziridines. Yields refer to isolated products. 
2.2 Carbonic anhydrase activation. 
To the best of our knowledge, this is the first study which evaluates the activation profile of different β-
aminochalcogenides. For this reason, we investigated the CA activating properties of amines 3a-g, 5a-I 
and 7a-g against 4 catalytically active and physiologically relevant hCA isoforms, the hCA I, II, VA and 
VII. Amphetamine (AMP) and histamine (HIST) were used as standard activators and shown in Table 
1.  
Table 1. Activation data of human CA isoforms I, II, VA and VII with compounds 3a-g, 5a-i, 7a-g, 
AMP and HIST by a stopped flow CO2 hydrase assay.33 
KA (µM)* 
Cmp hCA I hCA II hCA VA hCA VII  
3a 11.8 >100 12.4 23.4  
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3b 9.5 >100 13.3 23.2  
3c 13.5 >100 12.9 11.4  
3d 7.7 >100 12.4 14.8  
3e 9.7 >100 43.7 21.8  
3f 8.8 >100 10.2 14.8  
3g 7.9 >100 11.6 14.3  
5a 9.9 >100 14.7 20.6  
5b 5.2 >100 9.1 10.4  
5c 12.1 >100 20.0 14.2  
5d 6.0 >100 20.9 21.4  
5e 21.4 >100 20.3 23.3  
5f 19.6 >100 13.1 13.4  
5g 22.1 45.1 14.0 12.1  
5h 6.3 >100 6.6 10.1  
5i 5.9 >100 8.3 11.4  
7a 9.9 >100 14.2 41.2  
7b 8.2 >100 4.0 21.9  
7c 4.6 >100 3.3 44.9  
7d 9.5 >100 9.4 14.3  
7e 12.6 >100 20.2 44.7  
7f 5.1 >100 4.7 8.9  
7g 13.3 >100 13.7 11.0  
AMPa >100 >100 0.81 0.91  
HISTa 2.1 >100 0.01 37.5  
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* Mean from 3 different assays, by a stopped flow technique (errors were in the range of ± 5-10 % of the 
reported values). a Data from Ref.21  
The following SAR can be observed regarding the activation data of Table 1: 
i) The cytosolic, widespread isoform hCA II was not activated by these amines except for compound 5g 
which showed an activation constant of 45.1 µM. 
ii) The widely abundant cytosolic isozyme hCA I was moderately activated by most of the compounds 
here studied. β-Aminosulfides 3a-g showed KAs spanning between 7.7 to 13.5 µM. The presence of the 
bromine atom on aromatic ring plays a crucial role in modulation of activity. Indeed, bromine in position 
3 decreased the potency almost 2 times for compound 3d and 1.5 time when Br is placed in position 4 
(3d). The replacement of the sulfur with selenium or tellurium in compounds 3a, 5a and 7a did not 
influence significantly the activity (KAs of 11.8 to 9.9 µM). On the other hand, this replacement from 
sulfur to tellurium influenced the potency for the analogous compounds 3f, 5h and 7f. Indeed, such 
structures showed an increased activity moving within the chalcogen series, from sulfur to tellurium 
(KAs 8.8 to 5.1 µM). A different trend was observed for β-aminochalcogenides with isopropyl moiety 
(3g, 5i and 7g). Compound 3g showed a KA of 7.9 µM and the activity increases with the passage of 
selenium analog 5i (KA 5.9 µM), but this time, organo-tellurium compound 7g showed a less activating 
effects near two time than 3g (KA 13.3 µM). 
iii) The mitochondrial isoform hCA VA, involved in different metabolic pathway such as ureagenesis, 
lipogenesis and neoglucogenesis,34 was also activated by β-aminochalcogenides 3a-g, 5a-I and 7a-g 
with KAs ranging between 3.3 and 43.7 µM (Table 1). The best activators against this isoform were 
compounds with para substitution 7b and 7c with a KAs of 4.0 and 3.3 µM respectively. Additional 
substitution (7d) or replacement with a more bulky scaffold (7e) decreases the activity (KA 9.4 and 20.2 
µM respectively). On the other hand, β-aminosulfides 3a-g showed a flat SAR against hCA VA with 
KAs ranging in a narrow interval of 10.2 to 13.3 µM except for compound 3e with KA of 43.7 µM. It 
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should be noted that, also for this isoform, replacing the chalcogen atom within the homologous series of 
compounds 3f, 5h and 7f results in  increased potency moving from sulfur- to tellurium-containing 
derivatives (KAs 10.2 to 4.7 µM). These compounds remained, in any case, less effective on 
mitochondrial hCA compared to the psychotropic amine AMP. 
iv) The brain-associated cytosolic CA isoform, hCA VII,35 is moderately activated by compounds here 
reported, with activation constants in the range of 8.9-44.9 µM. The less active compounds (7a, 7c and 
7e) contain a tellurium atom. Contrarily, all other analog compounds such as 3a, 5a and 5e showed near 
two time more efficacy than them (KAs 20.4-23.4 versus 41.2-44.9 µM). It is interesting to note there 
were not differences between the activating effects of β-aminosulfides 3a-g and β-aminoselenides 5a-i. 
2.3 Antioxidant assays. 
In order to develop novel hCA activators with antioxidant properties, we also evaluated the thiol 
peroxidase-like properties of selected β-arylchalcogeno amines. Therefore, the activity of sulfides 3a,c, 
selenides 5a,e,l and tellurides 7a-c,f as mimics of glutathione peroxidase (GPx) was assessed by using 
the dithiothreitol (DTT) oxidation test36-39 and the GSH/GR coupled assay.39-40 Results of this 
investigation are reported in Table 2.  
Table 2. Thiol peroxidase-like activity of β -arylchalcogeno amines according to different methods. 
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Entry Compound DTT (T50)a,b,c GSH (T50)a,d
1
2
3
5
6
5a
5e
5i
7a
7b
442 (±42)
434 (±38)
398 (±54)
<60
<60
24 (±7)
21 (±6)
28 (±6)
<5
<5
7
8
9
10
7c
7f
N-Ts-5i
N-Ts-7f
<60
<60
3186 (±198)
600 (±61)
<5
<5
129 (±16)
14 (±3)
4 5h 402 (±48) 32 (±9)
 
[a] T50 is the time required, in seconds, to reduce the initial thiol concentration with 50% after the 
addition of H2O2; data in parenthesis are the experimental error. [b] DTT oxidation was monitored by the 
mean of 1H NMR spectroscopy; 10 mol % of organoselenide and 1 mol % of organotelluride with 
respect to the thiol were used. [c] T50 for PhSeSePh (commonly used reference compound) was found to 
be 796 (±84) seconds, according to DTT oxidation test. [d]NADPH consumption was monitored by UV 
spectroscopy (340 nm); 10 mol % of organoselenide and 1 mol % of organotelluride with respect to 
GSH were used.  
Whilst aminosulfides did not show significant catalytic properties (T50 >> 24 h for DTT assay), 
according both tests, all tested organoselenides and organo-tellurides exhibited remarkable catalytic 
antioxidant activity. Particularly, as expected, β-aryltelluro amines 7a-c,f proved to behave as excellent 
catalysts, being able to promote DTT and GSH oxidation in 2 minutes and in 15 seconds, respectively.39 
As previously reported, aminoselenides and aminotellurides bearing a free amino function behave as 
better catalysts with respect to their N-Ts protected analogues (Table 2, entries 3, 7 vs entries 8, 9);39 
this suggests important criteria in order to maintain both the hCA activator and the GPx-like properties. 
3. Conclusions 
 10 
We have used a fast and easy synthetic strategy to obtain ring opening reactions of strained heterocycles 
with chalcogen-containing nucleophiles to afford novel CAA activators. Many of them showed an 
interesting pattern of activation against four of the most important physiologic carbonic anhydrase 
isoforms such as the cytosolic enzymes hCA I, II and VII, but also, against the mitochondrial isoform 
hCA VA. Compounds with selenium and in particular tellurium atoms are also able to prevent the 
generation of ROS metabolites that cause oxidative stress and cellular damage. In this context, CAAs 
may be used in the memory therapy and cognitive neurodegenerative disorders where the levels of ROS 
are particular high, but also in the metabolic pathologies where is present a decreased function of hCA 
VA without increased ROS levels. 
4. Experimental Part 
4.1. General 
Anhydrous solvents and all reagents were purchased from Sigma-Aldrich, Alfa Aesar and TCI. All 
reactions involving air- or moisture-sensitive compounds were performed under a nitrogen atmosphere 
using dried glassware and syringes techniques to transfer solutions. Nuclear magnetic resonance (1H-
NMR, 13C-NMR, 19F NMR, 77Se-NMR, and 125Te) spectra were recorded using a Bruker Advance III 
400 MHz spectrometer in DMSO-d6. (PhSe)2 was used as an external reference for 77Se NMR (δ = 461 
ppm). Diphenyl ditelluride (PhTe)2 was used as an external reference for 125Te NMR (δ = 420 ppm). 
Chemical shifts are reported in parts per million (ppm) and the coupling constants (J) are expressed in 
Hertz (Hz). Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quadruplet; m, 
multiplet; brs, broad singlet; dd, double of doublets. The assignment of exchangeable protons (OH and 
NH) was confirmed by the addition of D2O. Analytical thin-layer chromatography (TLC) was carried 
out on Merck silica gel F-254 plates. Flash chromatography purifications were performed on Merck 
Silica gel 60 (230-400 mesh ASTM) as the stationary phase and ethyl acetate/n-hexane were used as 
eluents. Melting points (mp) were measured in open capillary tubes with a Gallenkamp MPD350.BM3.5 
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apparatus and are uncorrected. The solvents used in MS measures were acetone, acetonitrile 
(Chromasolv grade), purchased from Sigma-Aldrich (Milan - Italy), and mQ water 18 MΩ, obtained 
from Millipore's Simplicity system (Milan-Italy). The mass spectra were obtained using a Varian 1200L 
triple quadrupole system (Palo Alto, CA, USA) equipped by Electrospray Source (ESI) operating in both 
positive and negative ions. Stock solutions of analytes were prepared in acetone at 1.0 mg mL-1 and 
stored at 4°C. Working solutions of each analyte were freshly prepared by diluting stock solutions in a 
mixture of mQ H2O/ACN 1/1 (v/v) up to a concentration of 1.0 µg mL-1 The mass spectra of each 
analyte were acquired by introducing, via syringe pump at 10 µL min-1, of the its working solution. 
Raw-data were collected and processed by Varian Workstation Vers. 6.8 software. The HPLC was 
performed by using a Waters 2690 separation module coupled with a photodiode array detector (PDA 
Waters 996) using a Nova-Pak C18 4 μm 3.9 mm × 150 mm (Waters) silica-based reverse phase 
column. The sample was dissolved in 10% acetonitrile/H2O and an injection volume of 45 μL. The 
mobile phase (flow rate 1.0 mL/min) was a gradient of H2O + trifluoroacetic acid (TFA) 0.1% (A) and 
acetonitrile + TFA 0.1% (B), with steps as follows: (A%/B%), 0− 10 min 90:10, 10−25 min gradient to 
60:40, 26:28 min isocratic 20:80, 29−35 min isocratic 90:10. TFA 0.1% in water as well in acetonitrile 
was used as counterion. All compounds reported here were ≥95% HPLC pure. 
4.2. General Procedure for the synthesis of β-arylthio- and β-arylseleno-amines: 
Potassium hydroxide (1.1 eq.) was added to a solution of thiol 1a-e or selenol 4a-g (1.0 eq.) in DMF (2 
mL) under inert atmosphere (N2) at 0°C. Then N-H aziridine 2a-c (1.2 eq.) was slowly added and the 
mixture was stirred at 0°c for 3 h. Afterwards the reaction was diluted with EtOAc (5 mL) and saturated 
aq. NH4Cl (2 mL) was added. The organic phase was collected and the aqueous phase was extracted 
with EtOAc (2 x 5 mL). The combined organic phases were dried over Na2SO4 and concentrated under 
reduced pressure. The residue was purified by flash column chromatography to yield the desired β -
arylthioamine 3 or β-arylselenoamine 5. 
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1-(Phenylthio)propan-2-amine (3a): 
Following the general procedure, thiophenol 1a (22 mg, 0.2 mmol) and 2-methylaziridine 2a (14 mg, 
0.24 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 1:2), 1-
(phenylthio)propan-2-amine 3a (17 mg, 51%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.23 (3H, d, J = 6.3 Hz), 2.49 (2H, bs, NH2), 2.84 (1H, dd, J = 
7.9,13.1 Hz, CHaHbS), 3.07 (1H, dd, J = 4.7, 13.1 Hz, CHaHbS), 3.09-3.17 (1H, m, CHNH2), 7.19-7.23 
(1H, m), 7.28-7.32 (2H, m), 7.38-7.41 (2H, m). 13C NMR (100 MHz, CDCl3): δ (ppm) 22.4, 43.6, 46.2, 
126.3, 129.0, 129.8, 135.9. All recorded spectroscopic data matched those reported in the literature.41 
 
1-((2-Bromophenyl)thio)propan-2-amine (3b) 
Following the general procedure, 2-bromobenzenethiol 1b (38 mg, 0.2 mmol) and 2-methylaziridine 2a 
(14 mg, 0.24 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 
1:2), 1-((2-bromophenyl)thio)propan-2-amine 3b (21 mg, 43%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.23 (3H, d, J = 6.3Hz), 2.23 (2H, bs, NH2), 2.83 (1H, dd, J = 
7.9,12.9 Hz, CHaHbS), 3.05 (1H, dd, J = 4.7, 12.9 Hz, CHaHbS), 3.11-3.19 (1H, m, CHNH2), 7.04 (1H, 
td, J = 1.6, 7.9 Hz), 7.23-7.28 (1H, m), 7.28, 7.33 (1H, m), 7.55 (1H, dd, J = 1.0, 7.9 Hz). 13C NMR (100 
MHz, CDCl3): δ (ppm) 22.8, 43.0, 45.9, 124.1, 126.9, 127.7, 128.9, 133.0, 137.4. MS (ESI, positive): 
246.2 [M+H]+. 
 
1-((3-Bromophenyl)thio)propan-2-amine (3c) 
Following the general procedure, 3-bromobenzenethiol 1c (47 mg, 0.25 mmol) and 2-methylaziridine 2a 
(17 mg, 0.30 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 
1:2), 1-((3-bromophenyl)thio)propan-2-amine 3c (33 mg, 54%). 
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1 HMR (400 MHz, CDCl3): δ (ppm) 1.18 (3H, d, J = 6.3 Hz), 1.86 (2H, bs, NH2), 2.78 (1H, dd, J = 7.9, 
13.0 Hz, CHaHbS), 3.02 (1H, dd, J = 4.7, 13.0, CHaHbS), 3.06-3.14 (1H, m, CHNH2), 7.13 (1H, t, J = 7.9 
Hz), 7.25- 7.31 (2H, m), 7.48 (1H, apt, J = 1.8 Hz). 13C NMR (100 MHz, CDCl3): δ (ppm) 22.8, 43.6, 
46.0, 122.7, 127.5, 128.9, 130.1, 131.4, 138.7. MS (ESI, positive): 246.6 [M+H]+. 
 
1-((4-Bromophenyl)thio)propan-2-amine (3d) 
Following the general procedure, 4-bromobenzenethiol 1d (38 mg, 0.2 mmol) and 2-methylaziridine 2a 
(14 mg, 0.24 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 
1:2), 1-((4-bromophenyl)thio)propan-2-amine 3d (30 mg, 61%). 
1 H NMR (400 MHz, CDCl3): δ (ppm) 1.13 (3H, d, J = 6.3 Hz), 1.78 (2H, bs, NH2), 2.72 (1H, dd, J = 
8.0, 13.1, CHaHbS), 2.96 (1H, dd, J = 4.6, 13.1, CHaHbS), 2.99-3.08 (1H, m, CHNH2), 7.18 (2H, apd, J = 
8.5 Hz), 7.35 (2H, apd, J = 8.5 Hz). 13C NMR (100 MHz, CDCl3): δ (ppm) 22.8, 43.9, 45.9, 119.8, 
130.89, 131.84, 135.7. MS (ESI, positive): 246.3 [M+H]+. 
 
1-(Pyrimidin-2-ylthio)propan-2-amine (3e) 
Following the general procedure, pyrimidine-2-thiol 1e (23 mg, 0.2 mmol) and 2-methylaziridine 2a (14 
mg, 0.24 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 1:2), 
1-(pyrimidin-2-ylthio)propan-2-amine 3e (14 mg, 41%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.25 (3H, d, J = 6.3 Hz), 2.09 (2H, bs, NH2), 3.09 (1H, dd, J = 
6.7, 12.9 Hz, CHaHbS), 3.33 (1H, dd, J = 4.9, 12.9 Hz, CHaHbS), 3.25-3.32 (1H, m, CHNH2), 6.96 (1H, 
t, J = 4.8 Hz), 8.50 (2H, d, J = 4.8 Hz). 13C NMR (100 MHz, CDCl3): δ (ppm) 22.5, 40.1, 46.8, 116.6, 
157.2, 127.2. MS (ESI, positive): 169.9 [M+H]+. 
 
(S)-1-Phenyl-3-(phenylthio)propan-2-amine (3f) 
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Following the general procedure, thiophenol 1a (22 mg, 0.2 mmol) and (S)-2-benzylaziridine 2b (32 mg, 
0.24 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 1:1), (S)-
1-phenyl-3-(phenylthio)propan-2-amine 3f (27 mg, 55%). All recorded spectroscopic data matched 
those reported in the literature.42 
 
(S)-3-Methyl-1-(phenylthio)butan-2-amine (3g) 
Following the general procedure, thiophenol 1a (28 mg, 0.25 mmol) and (S)-2-isopropylaziridine 2c (26 
mg, 0.30 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 1:1), 
(S)-3-methyl-1-(phenylthio)butan-2-amine 3g (28 mg, 57%). All recorded spectroscopic data matched 
those reported in the literature.41 
 
1-(Phenylselanyl)propan-2-amine (5a) 
Following the general procedure, benzeneselenol 4a (31 mg, 0.2 mmol) and 2-methylaziridine 2a (14 
mg, 0.24 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 1:2), 
1-(phenylselanyl)propan-2-amine 5a (21 mg, 48%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.19 (3H, dd, J = 6.3, 12.4 Hz), 2.45 (2H, bs, NH2), 2.84 (1H, dd, 
J = 7.7, 12.2 Hz, CHaHbSe), 3.05 (1H, dd, J = 4.8, 12.2 Hz, CHaHbSe), 3.08-3.16 (1H, m, CHNH2), 
2.24-2.30 (3H, m), 7.52-7.56 (2H, m). 13C NMR (100 MHz, CDCl3): δ (ppm) 23.1, 38.7, 46.7, 127.0, 
129.1, 130.0, 132.8. 77Se NMR(76 MHz, CDCl3): δ (ppm) 254.1. MS (ESI, positive): 216.5 [M+H]+. 
 
1-(p-Tolylselanyl)propan-2-amine (5b) 
Following the general procedure, 4-methylbenzeneselenol 4b (43 mg, 0.25 mmol) and 2-methylaziridine 
2a (17 mg, 0.30 mmol) gave, after purification by flash column chromatography (petroleum 
ether:EtOAc 1:2), 1-(p-tolylselanyl)propan-2-amine 5b (30 mg, 53%). 
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1H NMR (400 MHz, CDCl3): δ (ppm) 1.18 (3H, d, J = 6.3 Hz), 2.31 (3H, s), 2.48 (2H, bs, NH2), 2.79 
(1H, dd, J = 7.9, 12.4 Hz, CHaHbSe), 2.99 (1H, dd, J = 4.8, 12.4 Hz, CHaHbSe), 3.04-3.12 (1H, m, 
CHNH2), 7.07 (2H, apd, J = 8.0 Hz), 7.42 (2H, apd, J = 8.0 Hz). 13C NMR (100 MHz, CDCl3): δ (ppm) 
21.1, 23.0, 38.8, 46.7, 125.9, 133.4, 137.2. 77Se NMR (76 MHz, CDCl3): δ (ppm) 246.7. MS (ESI, 
positive): 230.2 [M+H]+. 
 
1-(o-Tolylselanyl)propan-2-amine (5c) 
Following the general procedure, 2-methylbenzeneselenol 4c (34 mg, 0.20 mmol) and 2-methylaziridine 
2a (14 mg, 0.24 mmol) gave, after purification by flash column chromatography (petroleum 
ether:EtOAc 1:2), 1-(o-tolylselanyl)propan-2-amine 5c (31 mg, 67%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.20 (3H, d, J = 6.3 Hz), 2.08 (2H, bs, NH2), 2.42 (3H, s), 2.80 
(1H, dd, J = 7.9, 12.2 Hz, CHaHbSe), 3.01 (1H, dd, J = 4.8, 12.2 Hz, CHaHbSe), 3.07-3.15 (1H, m, 
CHNH2), 7.09 (1H, td, J = 1.7, 7.4 Hz), 7.14 (1H, td, J = 1.3, 7.4 Hz), 7.14-7.19 (1H, m), 7.44 (1H, apd, 
J = 7.6 Hz). 13C NMR (100 MHz, CDCl3): δ (ppm) 22.4, 23.3, 37.6, 46.7, 126.5, 126.8, 130.0, 131.0, 
131.8, 139.5. 77Se NMR (76 MHz, CDCl3): δ (ppm) 206.7. MS (ESI, positive): 229.8 [M+H]+. 
 
1-((2,6-Dimethylphenyl)selanyl)propan-2-amine (5d) 
Following the general procedure, 2,6-dimethylbenzeneselenol 4d (37 mg, 0.20 mmol) and 2-
methylaziridine 2a (14 mg, 0.24 mmol) gave, after purification by flash column chromatography 
(petroleum ether:EtOAc 1:2), 1-((2,6-dimethylphenyl)selanyl)propan-2-amine 5d (20 mg, 42%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.21 (3H, d, J = 6.4 Hz), 2.58 (6H, s), 2.70 (1H, dd, J = 7.3, 12.0 
Hz, CHaHbSe), 2.79 (1H, dd, J = 5.5, 12.0 Hz, CHaHbSe) 2.92-3.08 (3H, m, CHNH2 partially overlapped 
con NH2), 7.07-7.14 (3H, m). 13C NMR (100 MHz, CDCl3): δ (ppm) 22.4, 24.7, 47.6, 127.7, 128. 4, 
136.5, 143.0. MS (ESI, positive): 244.1 [M+H]+. 
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1-((4-Methoxyphenyl)selanyl)propan-2-amine (5e) 
Following the general procedure, 4-methoxybenzeneselenol 4e (56 mg, 0.30 mmol) and 2-
methylaziridine 2a (21 mg, 0.36 mmol) gave, after purification by flash column chromatography 
(petroleum ether:EtOAc 1:2), 1-((4-methoxyphenyl)selanyl)propan-2-amine 5e (40 mg, 55%). 
1 H NMR (400 MHz, CDCl3): δ (ppm) 1.17 (3H, d, J = 6.3 Hz), 2.40 (2H, bs, NH2), 2.73 (1H, dd, J = 
8.0, 12.3 Hz, CHaHbSe), 2.93 (1H, dd, J = 4.7,12.3 Hz, CHaHbSe), 3.0-3.08 (1H, m, CHNH2), 3.78 (3H, 
s, CH3O), 6.80 (2H, apd, J = 8.6 Hz), 7.48 (2H, apd, J = 8.6 Hz). 13C NMR (100 MHz, CDCl3): δ (ppm) 
22.9, 39.6, 46.6, 55.3, 114.8, 119.6, 135.7, 159.3. MS (ESI, positive): 245.8 [M+H]+. 
 
1-((4-Fluorophenyl)selanyl)propan-2-amine (5f) 
Following the general procedure, 4-fluorobenzeneselenol 4f (35 mg, 0.20 mmol) and 2-methylaziridine 
2a (14 mg, 0.24 mmol) gave, after purification by flash column chromatography (petroleum 
ether:EtOAc 1:2), 1-((4-fluorophenyl)selanyl)propan-2-amine 5f (33 mg, 71%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.17 (3H, d, J = 6.3 Hz), 2.24 (2H, bs, NH2), 2.78 (1H, dd, J = 
7.9, 12.3 Hz, CHaHbSe), 2.97 (1H, dd, J = 4.8, 12.3 Hz, CHaHbSe), 3.01-3.1 (1H, m, CHNH2), 6.95 (2H, 
apt, J = 8.7 Hz), 7.50 (2H, apdd, J = 8.7 Hz). 13C NMR (100 MHz, CDCl3): δ (ppm) 23.1, 39.5, 46.6, 
116.3 (d, 2JC-F = 21.5 Hz), 124.2 (4JC-F = 3.4 Hz), 135.4 (3JC-F = 7.9 Hz), 162.4 (1JC-F = 247.1 Hz). 77Se 
NMR (76 MHz, CDCl3): δ (ppm) 251.0. 19F NMR (376 MHz, CDCl3): δ (ppm) -114.6 (tt, J = 5.4, 8.7 
Hz). MS (ESI, positive): 234.4 [M+H]+. 
 
4-((2-Aminopropyl)selanyl)-N,N-dimethylaniline (5g) 
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Following the general procedure, 4-(dimethylamino)benzeneselenol 4g (40 mg, 0.20 mmol) and 2-
methylaziridine 2a (14 mg, 0.24 mmol) gave, after purification by flash column chromatography 
(petroleum ether:EtOAc 1:2), 4-((2-aminopropyl)selanyl)-N,N-dimethylaniline 5g (32 mg, 62%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.18 (3H, d, J = 6.4 Hz), 2.64 (2H, bs, NH2), 2.69 (1H, dd, J = 
8.2, 12.4 Hz, CHaHbSe), 2.90 (1H, dd, J = 4.7, 12.4 Hz, CHaHbSe), 2.94 (6H, s, (CH3)2N), 3.01-3.09 
(1H, m, CHNH2), 6.61 (2H, apd, J = 8.8 Hz), 7.43 (2H, apd, J = 8.8 Hz). 13C NMR (100 MHz, CDCl3): 
δ (ppm) 22.6, 39.4, 40.3, 46.7, 133.1, 113.9, 136.0, 150.2. MS (ESI, positive): 258.8 [M+H]+. 
 
(S)-1-Phenyl-3-(phenylselanyl)propan-2-amine (5h) 
Following the general procedure, benzeneselenol 4a (31 mg, 0.2 mmol) and (S)-2-benzylaziridine 2b (32 
mg, 0.24 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 1:1), 
(S)-1-phenyl-3-(phenylselanyl)propan-2-amine 5h (37 mg, 64%). All recorded spectroscopic data 
matched those reported in the literature.42 
 
(S)-3-Methyl-1-(phenylselanyl)butan-2-amine (5i) 
Following the general procedure, benzeneselenol 4a (39 mg, 0.25 mmol) and (S)-2-isopropylaziridine 2c 
(26 mg, 0.30 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 
1:1), (S)-3-methyl-1-(phenylselanyl)butan-2-amine 5i (37 mg, 61%). All recorded spectroscopic data 
matched those reported in the literature.43 
 
4.3. General Procedure for the synthesis of β-aryltelluro amines 
Sodium borohydride (3.0 eq.) was added to a suspension of diaryl ditelluride 6a-e (1.0 eq.) in dry EtOH 
(2 mL) under inert atmosphere (N2) at 0°C. Then N-H aziridine 2a-c (2.4 eq.) was slowly added and the 
mixture was allowed to warm to room temperature and then stirred 2 h. Afterwards the reaction was 
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diluted with EtOAc (5 mL) and saturated aq. NH4Cl (2 mL) was added. The organic phase was collected 
and the aqueous phase was extracted with EtOAc (2 x 5 mL). The combined organic phases were dried 
over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column 
chromatography to yield the desired β-aryltelluroamine 7. 
 
1-(Phenyltellanyl)propan-2-amine (7a) 
Following the general procedure, 1,2-diphenylditellane 6a (41 mg, 0.1 mmol) and 2-methylaziridine 2a 
(14 mg, 0.24 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 
1:2), 1-(phenyltellanyl)propan-2-amine 7a (28 mg, 53%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.23 (3H, d, J = 6.2 Hz), 2.31 (2H, bs, NH2), 2.95 (1H, dd, J = 
7.0, 11.8 Hz, CHaHbTe), 3.11 (1H, dd, J = 5.2, 11.8 Hz, CHaHbTe), 3.14-3.21 (1H, m, CHNH2), 7.2-
7.24 (2H, m), 7.28-7.32 (1H, m), 7.75-7.78 (2H, m). 13 C NMR (100 MHz, CDCl3): δ (ppm) 21.7, 24.3, 
47.8, 111.6, 127.7, 129.2, 138.4. 125Te NMR (126 MHz, CDCl3): δ (ppm) 390.5. MS (ESI, positive): 
266.1 [M+H]+. 
 
1-(p-Tolyltellanyl)propan-2-amine (7b) 
Following the general procedure, 1,2-di-p-tolylditellane 6b (44 mg, 0.1 mmol) and 2-methylaziridine 2a 
(14 mg, 0.24 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 
1:2), 1-(p-tolyltellanyl)propan-2-amine 7b (36 mg, 65%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.19 (3H, d, J = 6.2 Hz), 2.15 (2H, bs, NH2), 2.33 (3H, s), 2.87 
(1H, dd, J = 7.1, 11.9 Hz, CHaHbTe), 3.04 (1H, dd, J = 5.1, 11.9 Hz, CHaHbTe), 3.08-3.15 (1H, m, 
CHNH2), 7.01 (2H, apd, J = 7.9 Hz), 7.64 (2H, apd, J = 7.09 Hz). 13C NMR (400 MHz, CDCl3): δ (ppm) 
21.2, 22.0, 24.4, 47.7, 107.3, 130.2, 137.7, 138.8. 125Te NMR (126 MHz, CDCl3): δ (ppm) 377.1. MS 
(ESI, positive): 280.4 [M+H]+. 
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1-((4-Methoxyphenyl)tellanyl)propan-2-amine (7c) 
Following the general procedure, 1,2-bis(4-methoxyphenyl)ditellane 6c (47 mg, 0.1 mmol) and 2-
methylaziridine 2a (14 mg, 0.24 mmol) gave, after purification by flash column chromatography 
(petroleum ether:EtOAc 1:2), 1-((4-methoxyphenyl)tellanyl)propan-2-amine 7c (41 mg, 70%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.21 (3H, d, J = 6.3 Hz), 2.86 (1H, dd, J = 7.1, 12.0 Hz, 
CHaHbTe), 2.92 (2H, bs, NH2), 2.99 (1H, dd, J = 5.5, 12.0 Hz, CHaHbTe), 3.08-3.16 (1H, m, CHNH2), 
3.78 (3H, s, CH3O), 6.75 (2H, apd, J = 8.7 Hz), 7.69 (2H, apd, J = 8.7 Hz). 13C NMR (100 MHz, 
CDCl3): δ (ppm) 21.3, 23.9, 47.9, 55.1, 100.3, 115.2, 141.0, 159.8. 125Te NMR (126 MHz, CDCl3): δ 
(ppm) 379.8. MS (ESI, positive): 295.9 [M+H]+. 
 
1-((3,4,5-Trimethoxyphenyl)tellanyl)propan-2-amine (7d) 
Following the general procedure, 1,2-bis(3,4,5-trimethoxyphenyl)ditellane 6d (59 mg, 0.1 mmol) and 2-
methylaziridine 2a (14 mg, 0.24 mmol) gave, after purification by flash column chromatography 
(petroleum ether:EtOAc 1:2), 1-((3,4,5-trimethoxyphenyl)tellanyl)propan-2-amine 7d (43 mg, 61%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.22 (3H, t, J = 6.2 Hz), 2.19 (2H, bs, NH2), 2.93 (1H, dd, J = 7.1, 
11.8 Hz, CHaHbTe), 3.09 (1H, dd, J = 5.2, 11.8 Hz, CHaHbTe), 3.13-3.21 (1H, m, CHNH2), 3.83 (3H, s), 
3.85 (6H, s) 6.97 (2H, s). 13C NMR (100 MHz, CDCl3): δ (ppm) 22.5, 24.5, 47.8, 56.3, 60.9, 104.2, 
116.4, 138.4, 153.4. 125Te NMR (126 MHz, CDCl3) δ (ppm): 434.6. MS (ESI, positive): 356.4 [M+H]+. 
 
(S)-1-Phenyl-3-(phenyltellanyl)propan-2-amine (7f) 
Following the general procedure, 1,2-diphenylditellane 6a (41 mg, 0.1 mmol) and (S)-2-benzylaziridine 
2b (32 mg, 0.24 mmol) gave, after purification by flash column chromatography (petroleum 
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ether:EtOAc 1:1), (S)-1-phenyl-3-(phenyltellanyl)propan-2-amine 7f (39 mg, 57%). All recorded 
spectroscopic data matched those reported in the literature.26 
 
(S)-3-Methyl-1-(phenyltellanyl)butan-2-amine (7g) 
Following the general procedure, benzeneselenol 4a (41 mg, 0.1 mmol) and (S)-2-isopropylaziridine 2c 
(26 mg, 0.30 mmol) gave, after purification by flash column chromatography (petroleum ether:EtOAc 
1:1), (S)-3-methyl-1-(phenyltellanyl)butan-2-amine 7g (35 mg, 60%). All recorded spectroscopic data 
matched those reported in the literature.39 
 
4.4 Carbonic Anhydrase enzyme activation assay 
An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay the 
catalytic activity of various CA isozymes for CO2 hydration reaction.33 Phenol red (at a concentration of 
0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 10 mM Hepes (pH 
7.5) as buffer and 0.1 M Na2SO4 (for maintaining constant ionic strength), following the CA-catalyzed 
CO2 hydration reaction for a period of 10 s at 25 °C. The CO2 concentrations ranged from 1.7 to 17 mM 
for the determination of the kinetic parameters and activation constants. For each activator at least six 
traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The 
uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. 
Stock solutions of activators (10 mM) were prepared in distilled-deionized water and dilutions up to 1 
nM were done thereafter with the assay buffer. Activator and enzyme solutions were pre-incubated 
together for 15 min (standard assay at room temperature) prior to assay, in order to allow for the 
formation of the E–A complex. The activation constant (KA), defined similarly with the inhibition 
constant KI, can be obtained by considering the classical Michaelis–Menten equation (Eq. (1)), which 
has been fitted by non-linear least squares by using 
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PRISM 3: 
V=
Vmax
1 + KM / [S] (1 + [A]f / KA)
(1)
 
Where [A]f is the free concentration of activator. Working at substrate concentrations considerably 
lower than KM ([S] << KM), and considering that [A]f can be represented in the form of the total 
concentration of the enzyme ([E]t) and activator ([A]t), the obtained competitive steady-state equation 
for determining the activation constant is given by Eq. (2): 
V=
KA
 + ([A]t
 - 0.5
  
([A]t
 + [E]t
 + KA) - ([A]t + [E]t
 + KA)2
 - 4[A]t
 
[E]t)1/2
V0
 KA
(2)
 
Where V0 represents the initial velocity of the enzyme-catalyzed reaction in the absence of activator. 
The enzymes were recombinant ones, prepared in-house as reported earlier.28-31 
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